San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Regulus Therapeutics is raising $34,624,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jay Hagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Regulus Therapeutics
Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is located in San Diego, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.

To learn more about Regulus Therapeutics, visit http://www.regulusrx.com/

Contact:
Jay Hagan, Chief Executive Officer
858-202-6300
jhagan@regulusrx.com
https://www.linkedin.com/in/jayhagan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved